One of the first studies engineering exosomes with miRNAs for treatment purposes loaded miR-let7a inside GE11 peptide-positive cells, a modification designed to target epidermal growth factor receptor (EGFR)-positive cells, expressed in a high variety of tumors such as in breast cancer. Here, EGFR is linked to breast carcinoma.